Interim Report

January–June 2026

Q2

1 April–30 June 2026

- Net sales amounted to SEK 4,686m (3,987), up 18%.
- Adjusted EBITA amounted to SEK 471m (378), up 24%.
- The adjusted EBITA margin amounted to 10.0% (9.5).
- EBIT amounted to SEK 349m (249), and profit for the quarter amounted to SEK 225m (133).
- Earnings per share before and after dilution amounted to SEK 0.57 (0.34).
- Return on net working capital (EBITA/NWC) amounted to 68.7% (65.4).
- Adjusted cash flow from operating activities amounted to SEK 330m (211).

1 January–30 June 2026

- Net sales amounted to SEK 9,207m (7,982), up 15%.
- Adjusted EBITA amounted to SEK 912m (742), up 23%.
- The adjusted EBITA margin was 9.9% (9.3).
- EBIT amounted to SEK 659m (487), and profit for the period amounted to SEK 422m (228).
- Earnings per share before and after dilution amounted to SEK 1.07 (0.54).
- Return on net working capital (EBITA/NWC) amounted to 68.7% (65.4).
- Adjusted cash flow from operating activities amounted to SEK 749m (320).

"Steady growth that continues to outperform the market, with strong earnings leverage supported by the Group's increased scale. The adjusted EBITA margin increased to 10.0%. One new acquisition signed, and continued good visibility among many high-quality acquisition candidates."

Key performance indicators

Amounts in SEKm, unless otherwise stated

	1 April–30 June			1 January–30 June			Rolling 12 months	Full-year
	2026	2025	Change	2026	2025	Change	2025/2026	2025
Net sales	4,686	3,987	18%	9,207	7,982	15%	18,012	16,787
Adjusted EBITA*	471	378	24%	912	742	23%	1,765	1,594
Adjusted EBITA margin, %*	10.0%	9.5%	0.5 p.p.	9.9%	9.3%	0.6 p.p.	9.8%	9.5%
EBITA*	475	323	47%	903	634	42%	1,659	1,390
EBITA margin, %*	10.1%	8.1%	2 p.p.	9.8%	7.9%	1.9 p.p.	9.2%	8.3%
EBIT	349	249	40%	659	487	35%	1,181	1,009
Profit for the period	225	133	70%	422	228	85%	704	510
Earnings per share before and after dilution (SEK)	0.57	0.34	70%	1.07	0.54	101%	1.78	1.25
Earnings per share before and after dilution (SEK), adjusted*	0.57	0.34	70%	1.07	0.57	87%	1.78	1.28
Net debt/EBITDA**	2.37	1.84	0.53x	2.37	1.84	0.53x	2.37	2.26
Return on net working capital (EBITA/NWC), %*	68.7%	65.4%	3.4 p.p.	68.7%	65.4%	3.4 p.p.	68.7%	67.0%
Adjusted cash flow from operating activities*	330	211	57%	749	320	134%	1,814	1,385

* Refer to Note 5 for the calculation of alternative performance measures and the definitions section for further information about these performance indicators.
** EBITDA rolling 12 months adjusted for leases and items affecting comparability.

CEO'S COMMENTS

Continued steady growth

During the second quarter, our organic growth continued to outperform the market, and we reported a 5% increase in sales and a 6% increase in adjusted EBITA. In parallel, we took further steps to broaden our product portfolio and strengthen our position in Europe, signing a new acquisition agreement in early July. In total, sales increased by 18% during the quarter, and adjusted EBITA by 24%. The adjusted EBITA margin strengthened to 10.0%. Continued healthy and stable cash flows. Efficient capital utilisation supported an increase in EBITA/NWC to 69%.

All business areas report good growth

Organic growth remained favourable, driven once again this quarter by many small but varied advances within the companies, combined with Asker's increased scale and reach. We once again delivered overall earnings growth well above our financial target, clearly supported by Asker's active acquisition agenda over the past year. I am also pleased to see that the acquisitions made to date this year have started well.

Business Area North continued to grow organically, noting healthy profitability and stable margins. The move to and startup of the new warehouse in Gothenburg are proceeding according to plan, with the facility expecting to be fully operational by the end of the year.

Business Area West delivered another quarter of good earnings growth, underpinned by completed acquisitions and economies of scale from its growing home care operations.

Earnings continued to strengthen for Business Area Central, which reported a positive margin trend, driven primarily by completed acquisitions and an improved product mix.

The adjusted EBITA margin increased to 10.0% (9.5) for the Group as a whole.

Stability that provides flexibility

Steady demand for medical products in the healthcare sector provides a solid foundation for our business. This builds resilience across business cycles when combined with Asker's increased scale, geographic footprint and progressively broader product portfolio.

Steady demand generates consistent operating cash flows, in turn giving us the flexibility to complete acquisitions and invest in more efficient solutions, such as new warehouses.

During the quarter, we maintained a stable leverage and good acquisition capacity, while paying a dividend as well as larger-than-usual contingent considerations due to the strong performance of the companies.

Sustainability initiatives drive business

Our long-term sustainability initiatives aimed at ensuring a fair and sustainable value chain make a tangible contribution to our business. Our ESG investments of recent years have made a clear difference in various procurement processes, with our capacity to meet high environmental standards and maintain effective control over the value chain playing a crucial role in winning contracts.

In April, Asker was also awarded the highest rating, AAA, in the MSCI ESG Rating's first review of the company, an achievement we are very proud of.

Past halfway to our acquisition target for the year

In early July, we completed another acquisition, Murray Surgical, which strengthens and is a good complement to the HSL Group in surgical and medical products in Ireland.

Discontinuing an acquisition process is sometimes the right thing to do. After a long closing process, we agreed with the seller in the spring to terminate the acquisition of Kirstine Hardam. Instead, we are turning our focus to the other many attractive opportunities in our pipeline.

We continue to have good acquisition pipeline visibility. Our target is to complete acquisitions each year that contribute 10–12% to our EBITA growth. Now that six months of the year have passed, we have come more than halfway to achieving this acquisition target while also strengthening the Group's EBITA margin.

Value-generating growth over time

Our priority is to continue growing Asker through regular strategic acquisitions, decentralised accountability, gradual realisation of benefits from our enhanced capacity and market presence, and maintaining a focus on cash flow and capital efficiency.

By combining entrepreneurship and close proximity to customers with Asker's growing scale, we are creating a platform to continue driving progress in the healthcare sector and delivering on our financial targets.



Johan Falk,
CEO

Financial performance – Group

Net sales

Net sales for the second quarter amounted to SEK 4,686m (3,987), up 18% year-on-year, of which 5% was organic growth and 13% from acquisitions. Sales growth was driven by a favourable organic performance and the completion of acquisitions in the Business Areas West and Central.

Net sales in the January-June period amounted to SEK 9,207m (7,982), up 15%, of which 5% was organic growth and 12% from acquisitions, while exchange rates had a negative impact of –2%.

Adjusted EBITA, net financial items and profit for the period

Adjusted EBITA for the second quarter amounted to SEK 471m (378), up 24%, of which 6% was organic growth and 18% from acquisitions. Adjusted EBITA in the January-June period amounted to SEK 912m (742), up 23%, of which 7% was organic growth and 18% from acquisitions, while exchange rates had a negative impact of –2%. Growth was driven by sales growth and improved margins in established and newly acquired companies. The adjusted EBITA margin was 10.0% (9.5) for the second quarter and 9.9% (9.3) for the period.

Operating profit (EBIT) amounted to SEK 349m (249) for the second quarter and to SEK 659m (487) for the January-June period.

Net financial items amounted to SEK –65m (–77) for the second quarter and to SEK –118m (–181) for the January-June period. The lower net financial expense compared with the preceding year is primarily the result of unrealised foreign exchange rate gains on loans and derivatives, respectively. Tax amounted to SEK –59m (–39) for the second quarter and to SEK –119m (–78) for the January-June period, yielding an effective tax rate of 21% (23) for the quarter and 22% (25) for the period. Profit for the period amounted to SEK 225m (133) in the second quarter and to SEK 422m (228) for the January-June period.

Financial position and cash flow

Adjusted cash flow from operating activities amounted to SEK 330m (211) for the second quarter and to SEK 749m (320) for the January-June period. The increased cash flow for the quarter was primarily the result of favourable earnings growth and efficient working capital management. Furthermore, scheduled payments totalling SEK 463m were made during the quarter for contingent considerations, of which SEK 238m impacted cash flow from operating activities and SEK 226m impacted cash flow from investing activities. The contingent considerations paid were primarily attributable to acquisitions completed in 2022 and 2023, which fell due for payment at the end of 2025. During the quarter, the dividend of SEK 149m resolved on by the Annual General Meeting was also paid. Net debt increased to SEK 4,511m (2,886). Net debt in relation to adjusted EBITDA amounted to 2.37 (1.84). Return on net working capital (EBITA/NWC) increased to 68.7% (65.4). At the end of the quarter, cash and cash equivalents amounted to SEK 777m (1,325) and undrawn credit facilities to SEK 569m (657).

Items affecting comparability

Items affecting comparability amounted to SEK –4m (55) for the second quarter, of which SEK 9m (15) was related to acquisition and integration expenses, SEK –17m (39) to revaluations of contingent considerations, and SEK 3m (1) to other items affecting comparability. Items affecting comparability amounted to SEK 9m (108) for the January-June period, of which SEK 20m (37) was related to acquisition and integration expenses, SEK –14m (56) to revaluations of contingent considerations, and SEK 4m (15) to other items affecting comparability, with the year-on-year difference attributable to items affecting comparability related to the IPO in 2025.

Net sales per quarter



Adjusted EBITA per quarter



Adjusted EBITA growth
Jan–Jun 2026



Earnings per share

Profit for the period attributable to the Parent Company's shareholders amounted to SEK 219m (129) for the second quarter and to SEK 412m (220) for the period. Earnings per share, before and after dilution, amounted to SEK 0.57 (0.34) for the second quarter and SEK 1.07 (0.54) for the period. The average number of common shares outstanding, before and after dilution, used in the calculation of earnings per share was 383,036,497 for both the second quarter and the period, and 383,036,497 for the second quarter of 2025 and 353,294,482 for the period in 2025. Refer to Note 5 for a reconciliation and calculation. At the end of the period, the number of common shares outstanding totalled 383,036,497.

Financial targets and rolling 12-month outcomes

TARGET >15%	Adjusted EBITA growth per year	OUTCOME +21%
TARGET >10%	Adjusted EBITA margin (medium term)	OUTCOME 9.8%
TARGET >50%	Return on net working capital, EBITA/NWC	OUTCOME 69%
TARGET <2.5x	Net debt/ EBITDA*	OUTCOME 2.37x
TARGET >30%	Dividend policy	OUTCOME 0.39 SEK/SHARE (corresponding to 30%)

* EBITDA rolling 12 months adjusted for expenses attributable to leases and items affecting comparability.

Progress towards 2030 sustainability targets is on track

TARGET 2030 –42%	Reduced Scope 1 and 2 emissions*	STATUS AS PER 2025 –22% ON TRACK
TARGET 2030 –52%	Reduced Scope 3 emissions**	STATUS AS PER 2025 –40% ON TRACK
TARGET 2030 >90%	Code of Conduct for suppliers***	STATUS AS PER 2025 85% ON TRACK

* Reduced Scope 1 and 2 emissions as a percentage compared to the 2021 base year, market-based.
** Total Scope 3, category 1 emissions per SEK m gross profit (tCO_2e/SEKm).
*** Percentage of suppliers, based on sales, that have signed Asker's Code of Conduct or an equivalent code.

For all sustainability targets, refer to the 2025 Annual Report.

Financial performance – Business areas

Asker Healthcare Group focuses on northern, western and central Europe and currently has a presence in 19 countries. The Group also has a quality and audit office in Asia. The Group's operations are conducted in three business areas defined by geographical market, comprising North, West and Central.

Net sales per segment,
LTM, 1 July 2025 – 30 June 2026



Business Area North

North consists of Sweden, Norway, Finland, Estonia, Latvia and Lithuania. Operations are conducted through 18 subsidiaries. The average number of full-time equivalents during the period was 894 (784).

Financial performance
Net sales in the second quarter amounted to SEK 1,429m (1,265), up 13%, of which 10% was organic growth and 2% from acquisitions, while exchange rates had a positive impact of 1%. Adjusted EBITA for the second quarter amounted to SEK 193m (175), up 10%, and the adjusted EBITA margin amounted to 13.5% (13.9).

Net sales for the January–June period amounted to SEK 2,783m (2,527), up 10%, of which 8% was organic growth and 2% from acquisitions. Adjusted EBITA for the January–June period amounted to SEK 379m (352), up 8%, and the adjusted EBITA margin amounted to 13.6% (13.9). Operations in North continued to generate favourable organic growth during both the quarter and the first half of 2026, maintaining margins above 13% over the past 12 months. Work on the new distribution centre in Gothenburg proceeded according to plan. Testing and a gradual move to the new warehouse are underway, with efforts set to intensify in the autumn.

Adjusted EBITA growth – North
Jan–Jun 2026



Amounts in SEKm	1 April–30 June 2026	2025	Change	1 January–30 June 2026	2025	Change	Rolling 12 months 2025/2026	Full-year 2025
Net sales	1,429	1,265	13%	2,783	2,527	10%	5,465	5,210
Adjusted EBITA	193	175	10%	379	352	8%	708	681
Adjusted EBITA margin, %	13.5%	13.9%	–0.4 p.p.	13.6%	13.9%	–0.3 p.p.	13.0%	13.1%

Business Area West

West consists of the Netherlands, Belgium, Luxembourg, the UK, Ireland and Denmark. Operations are conducted through 18 subsidiaries. The average number of full-time equivalents during the period was 2,107 (1,972).

Financial performance
Net sales in the second quarter amounted to SEK 2,327m (2,021), up 15%, of which 2% was organic growth and 14% from acquisitions, while exchange rates had a negative impact of –1%. Adjusted EBITA for the second quarter amounted to SEK 224m (169), up 32%, and the adjusted EBITA margin amounted to 9.6% (8.4).

Net sales in the January–June period amounted to SEK 4,580m (4,029), up 14%, of which 4% was organic growth and 13% from acquisitions, while exchange rates had a negative impact of –3%. Adjusted EBITA for the January–June period amounted to SEK 438m (330), up 32%, and the adjusted EBITA margin amounted to 9.6% (8.2). The business area continued to consistently improve its sales and margins, driven by economies of scale and an expanded product and service offering. New acquisitions made a strong contribution from start, and the July acquisition of the Irish company Murray Surgical will further complement the product offering in the region.

Adjusted EBITA growth – West
Jan–Jun 2026



Amounts in SEKm	1 April–30 June 2026	1 April–30 June 2025	Change	1 January–30 June 2026	1 January–30 June 2025	Change	Rolling 12 months 2025/2026	Full-year 2025
Net sales	2,327	2,021	15%	4,580	4,029	14%	9,095	8,543
Adjusted EBITA	224	169	32%	438	330	32%	864	757
Adjusted EBITA margin, %	9.6%	8.4%	1.2 p.p.	9.6%	8.2%	1.4 p.p.	9.5%	8.9%

Business Area Central

Central consists of France, Germany, Austria, Switzerland, Slovakia, Poland and the Czech Republic. Operations are conducted through 18 subsidiaries. The average number of full-time equivalents during the period was 1,003 (760).

Financial performance
Net sales for the second quarter amounted to SEK 931m (701), up 33%, of which 2% was organic and 31% from acquisitions. Adjusted EBITA for the second quarter amounted to SEK 90m (57), up 56%, and the adjusted EBITA margin amounted to 9.6% (8.2).

Net sales in the January–June period amounted to SEK 1,844m (1,426), up 29%, of which 3% was organic growth and 28% from acquisitions, while exchange rates had a negative impact of –2%. Adjusted EBITA for the for the January–June period amounted to SEK 170m (112), up 52%, and the adjusted EBITA margin amounted to 9.2% (7.8). Acquisitions made over the past year complemented the business area's organic growth and supported the strong growth performance of recent quarters. The focus on margin-enhancing activities continued to generate positive results during the quarter.

Adjusted EBITA growth – Central
Jan–Jun 2026



	1 April–30 June			1 January–30 June			Rolling 12 months	Full-year
Amounts in SEKm	2026	2025	Change	2026	2025	Change	2025/2026	2025
Net sales	931	701	33%	1,844	1,426	29%	3,452	3,034
Adjusted EBITA	90	57	56%	170	112	52%	316	259
Adjusted EBITA margin, %	9.6%	8.2%	1.4 p.p.	9.2%	7.8%	1.4 p.p.	9.2%	8.5%

Other information

Employees
During the period, full-time equivalents in the Group averaged 4,053 (3,560), of which the Group function had 49 (44) full-time equivalents. The number of employees was 4,885 at the end of the period (4,248) and 4,559 at the start of the period.

Parent Company
Asker Healthcare Group AB (559184-9848) is the Parent Company of the Group. Net sales for the Parent Company amounted to SEK 8m (7) for the second quarter. Net financial items amounted to SEK –3m (–8) and loss before tax was SEK –6m (–20). Total assets amounted to SEK 7,607m (7,814) and total liabilities to SEK 3,282m (3,302). The Parent Company has 2 (2) employees.

Accounting policies
This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting, the Swedish Corporate Reporting Board's recommendation RFR 1 and the Swedish Annual Accounts Act. The information submitted in accordance with IAS 34.16A has been presented both in the consolidated financial statements and in other sections of this interim report. The interim report is presented in million Swedish kronor (SEKm) unless otherwise stated. Amounts in parenthesis refer to the preceding year. There may be differences in totals since individual items have been rounded to the nearest whole SEKm. The accounting policies have been applied as described in the Group's 2025 Annual Report.

None of the amendments to IFRS Accounting Standards that entered force during the year had any material impact on the consolidated financial statements. For more information, refer to the disclosures as described in the Group's 2025 Annual Report.

The Parent Company's financial statements have been prepared in accordance with the Swedish Corporate Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. RFR 2 means that the Parent Company for the legal entity is to apply all IFRS accounting standards and statements as adopted by the EU as far as possible within the framework of the Annual Accounts Act and taking into account the relationship between accounting and taxation.

Estimates and judgments
There have been no changes in the estimates and judgments described in the Group's most recently issued Annual Report for 2025.

Related-party transactions
No material transactions with related parties were conducted during the quarter. For further information on related-party transactions, refer to the Group's Annual Report.

Material risks and uncertainties
The Group's strategic and operational position, and the expected trend in its earnings and financial position, may be affected by risks and uncertainties that the Group is exposed to. Asker works continuously to identify and monitor risks so that it can leverage opportunities to achieve business targets or counteract such risks that the Group is unwilling to take. The material risks that are deemed to have the greatest impact on the Group are strategic and operational risks related to geopolitics and disruptions to the global supply chain, IT and information security-related risks and financial stability. In addition, the Group is impacted by financial risks such as currency risks, liquidity risks and refinancing risks.

Changes to risk during the quarter
The general uncertainty in global markets remains high. Company management is closely following developments and mitigation plans are followed up and adjusted as necessary. Increasing geopolitical unrest could disrupt supply chains, but the geopolitical situation did not impact the Group's financial position during the quarter. For more information on the Group's risks, refer to the risk section in the Group's Annual Report for 2025.

The Board of Directors and the CEO give their assurance that this interim report provides a true and fair overview of the operations, financial position and earnings of the Parent Company and of the Group, and describes material risks and uncertainties faced by the Parent Company and the companies that form the Group.
The content of the interim report was approved on 20 July 2026.

Danderyd, 21 July 2026

Asker Healthcare Group AB

Mikael Stöhr
Chairman of the Board

Nina Linander
Board member

Karl Petersson
Board member

Birgitta Stymne Göransson
Board member

Mikael Vinje
Board member

Joachim Zetterlund
Board member

Johan Falk
CEO

This report has not been reviewed by Asker Healthcare Group's auditors.

Financial statements – Group

Consolidated income statement

Amounts in SEKm	Note	1 April–30 June 2026	1 April–30 June 2025	1 January–30 June 2026	1 January–30 June 2025	Full-year 2025
Net sales	2	4,686	3,987	9,207	7,982	16,787
Cost of goods sold		–2,721	–2,357	–5,377	–4,723	–9,916
Gross profit		**1,966**	**1,630**	**3,830**	**3,259**	**6,871**
Selling expenses		–1,139	–968	–2,232	–1,937	–4,119
Administrative expenses		–509	–385	–982	–794	–1,680
Other operating income		24	17	42	25	54
Other operating expenses		7	–45	–1	–66	–117
Operating profit (EBIT)		**349**	**249**	**659**	**487**	**1,009**
Financial income		60	–8	154	159	222
Financial expenses		–124	–69	–272	–339	–572
Profit before tax		**284**	**172**	**541**	**306**	**659**
Income tax		–59	–39	–119	–78	–149
Profit for the period		**225**	**133**	**422**	**228**	**510**
Profit attributable to:						
Parent Company's shareholders		219	129	412	220	492
Non-controlling interests		6	4	11	8	18
Earnings per share before and after dilution (SEK)	5	0.57	0.34	1.07	0.54	1.25

Condensed consolidated statement of comprehensive income

Amounts in SEKm	1 April–30 June 2026	1 April–30 June 2025	1 January–30 June 2026	1 January–30 June 2025	Full-year 2025
Profit for the period	**225**	**133**	**422**	**228**	**510**
Other comprehensive income for the period					
Items that have been or can be reclassified to the income statement					
Translation differences for the period on translation of foreign operations	69	53	153	–167	–276
Total other comprehensive income for the period	69	53	**153**	–167	**–276**
Comprehensive income for the period	**295**	**186**	**576**	**60**	**234**
Of which, attributable to:					
Parent Company’s shareholders	288	182	565	53	216
Non-controlling interests	6	4	11	8	18

Condensed consolidated balance sheet

		30 June		31 December
Amounts in SEKm	Note	2026	2025	2025
ASSETS				
Goodwill		6,758	5,651	6,369
Other intangible assets		3,274	2,374	3,027
Tangible assets		1,877	1,474	1,780
Financial non-current assets		42	28	32
Deferred tax assets		86	83	94
Total non-current assets		**12,037**	**9,610**	**11,302**
Inventories		2,364	1,938	2,041
Accounts receivable		2,096	1,810	2,052
Other current receivables		557	525	495
Cash and cash equivalents		777	1,325	884
Total current assets		**5,794**	**5,598**	**5,472**
TOTAL ASSETS		**17,832**	**15,208**	**16,774**
EQUITY AND LIABILITIES				
Equity attributable to Parent Company's shareholders		6,978	6,386	6,555
Non-controlling interests		41	38	33
Total equity		**7,018**	**6,424**	**6,588**
Interest-bearing liabilities	3	4,256	3,361	4,224
Lease liabilities		728	654	727
Deferred tax liabilities		676	470	606
Other non-current liabilities and provisions	3	714	398	591
Total non-current liabilities		**6,374**	**4,883**	**6,149**
Interest-bearing liabilities	3	1,148	850	557
Lease liabilities		344	243	306
Accounts payable		1,672	1,348	1,610
Other current liabilities	3	1,274	1,460	1,565
Total current liabilities		**4,439**	**3,901**	**4,038**
TOTAL EQUITY AND LIABILITIES		**17,832**	**15,208**	**16,774**

Condensed consolidated statement of changes in equity

	30 June		31 December
Amounts in SEKm	2026	2025	2025
Opening balance	**6,588**	**3,502**	**3,502**
Comprehensive income for the period	**576**	**60**	**234**
Paid share issue*	–	1,426	1,426
Set-off issue*	–	1,439	1,439
Investment share programme	6	–	4
Dividends paid to Parent Company's shareholders	–149	–	–
Dividends paid to non-controlling interests	–2	–1	–15
Transactions attributable to non-controlling interests	–	–1	–1
Closing balance	**7,018**	**6,424**	**6,588**
Equity attributable to:			
Parent Company's shareholders	6,978	6,386	6,555
Non-controlling interests	41	38	33

* In conjunction with the IPO on 27 March 2025, Asker conducted a new share issue totalling SEK 1,500m, consisting of 21,428,571 shares at a subscription price of SEK 70 per share. Transaction costs for the full-year amounted to SEK 93m, which, net of tax, impacted equity in the amount of SEK 1,426m. In parallel, a directed set-off issue was conducted to repay existing shareholder loans. The value of shareholder loans with accrued interest amounted to SEK 1,439m, meaning that 20,552,600 new shares were issued at a subscription price of SEK 70 per share.

Condensed consolidated statement of cash flows

		1 April–30 June		1 January–30 June		Full-year
Amounts in SEKm	Note	2026	2025	2026	2025	2025
Operating profit (EBIT)		349	249	659	487	1,009
Adjustments for non-cash items*		235	204	474	391	839
Interest received		4	3	5	5	10
Interest paid		–59	–43	–115	–102	–201
Income tax paid		–83	–54	–145	–185	–337
		446	**359**	**879**	**595**	**1,321**
Change in current receivables		156	–55	106	–69	–87
Change in inventories		–132	–28	–137	–41	53
Change in current liabilities	4	–378	–65	–337	–165	41
Cash flow from operating activities		**92**	**211**	**511**	**320**	**1,328**
Investments in intangible and tangible assets		–112	–206	–212	–278	–590
Sale of intangible and tangible assets		43	–	47	–	15
Acquisition of subsidiaries (less acquired cash)	4	–354	–164	–522	–997	–2,331
Cash flow from investing activities		**–422**	**–370**	**–687**	**–1,275**	**–2,906**
New borrowings		–	–	–	4,104	5,098
Repayments of borrowings		–	–	–	–4,037	–4,258
Repayment of lease liabilities		–91	–67	–174	–134	–290
Changes in overdraft facilities		389	817	368	445	59
Share issue**		–	–18		1,407	1,407
Private placement for non-controlling interests		–	–	–	24	24
Dividends paid to Parent Company's shareholders		–149	–	–149	–	–
Dividends paid to holders of non-controlling interests		–2	–	–2	–1	–15
Cash flow from financing activities		**146**	**731**	**43**	**1,808**	**2,025**
Cash flow for the period		**–183**	**572**	**–132**	**854**	**447**
Cash and cash equivalents at the beginning of the period		945	735	884	490	490
Exchange rate differences in cash and cash equivalents		15	18	26	–19	–53
Cash and cash equivalents at the end of the period		**777**	**1,325**	**777**	**1,325**	**884**

* Pertains mainly to amortisation and revaluation of contingent considerations.
** The negative cash flow impact from the share issue in the second quarter of 2025 comprised final bank fees related to the IPO.

Condensed income statement for the Parent Company

	1 April–30 June		1 January–30 June		Full-year
Amounts in SEKm	2026	2025	2026	2025	2025
Net sales	8	7	11	11	19
Gross profit	**8**	**7**	**11**	**11**	**19**
Administrative expenses	–11	–19	–23	–42	–53
Other operating income and expenses	–	0	0	1	1
Operating loss	**–3**	**–12**	**–12**	**–31**	**–34**
Financial income and expenses	–3	–8	–3	34	67
Appropriations	0	0	0	0	43
Profit/loss before tax	**–6**	**–20**	**–15**	**3**	**76**
Income tax	–2	0	0	0	–19
Profit/loss for the period	**–8**	**–20**	**–15**	**3**	**58**

The Parent Company has no transactions to report in other comprehensive income, and subsequently the Parent Company's comprehensive income is consistent with profit/loss for the period.

Condensed balance sheet for the Parent Company

Amounts in SEKm	30 June 2026	30 June 2025	31 December 2025
ASSETS			
Financial non-current assets	3,585	3,573	3,578
Total non-current assets	**3,585**	**3,573**	**3,578**
Current assets	4,021	4,241	4,176
Cash and cash equivalents	1	0	0
Total current assets	**4,022**	**4,241**	**4,176**
TOTAL ASSETS	**7,607**	**7,814**	**7,754**
EQUITY AND LIABILITIES			
Restricted equity	1	1	1
Non-restricted equity	4,312	4,411	4,470
Total equity	**4,312**	**4,412**	**4,470**
Untaxed reserves	**–**	**91**	**–**
Provisions	**12**	**10**	**11**
Non-current liabilities	3,243	3,252	3,188
Current liabilities	39	50	84
Total liabilities	**3,282**	**3,302**	**3,273**
TOTAL EQUITY AND LIABILITIES	**7,607**	**7,814**	**7,754**

Notes

NOTE 1 Segment information

Amounts in SEKm	1 April–30 June 2026	1 April–30 June 2025	1 January–30 June 2026	1 January–30 June 2025	Full-year 2025
Net sales from external customers					
North	1,429	1,265	2,783	2,527	5,210
West	2,327	2,021	4,580	4,029	8,543
Central	931	701	1,844	1,426	3,034
Other and eliminations	–	–	–	–	–
Total net sales from external customers	**4,686**	**3,987**	**9,207**	**7,982**	**16,787**
Net sales from other operating segments					
North	21	23	43	47	93
West	25	15	43	27	72
Central	3	2	7	4	11
Other and eliminations	–49	–40	–93	–77	–175
Total net sales from other operating segments	**–**	**–**	**–**	**–**	**–**
Total net sales	**4,686**	**3,987**	**9,207**	**7,982**	**16,787**
Adjusted EBITA					
North	193	175	379	352	681
West	224	169	438	330	757
Central	90	57	170	112	259
Other and eliminations	–36	–24	–74	–52	–102
Total adjusted EBITA	**471**	**378**	**912**	**742**	**1,594**
Items affecting comparability (see definitions and Note 5)	4	–55	–9	–108	–204
EBITA					
North	195	192	374	330	625
West	231	169	445	335	743
Central	87	3	159	67	185
Other and eliminations	–37	–40	–75	–97	–163
Total EBITA	**475**	**323**	**903**	**634**	**1,390**
Amortisation of intangible assets	–126	–74	–245	–148	–381
Operating profit (EBIT)	**349**	**249**	**659**	**487**	**1,009**
Net financial items	–65	–77	–118	–181	–350
Profit before tax	**284**	**172**	**541**	**306**	**659**

NOTE 2 Net sales

Asker's companies primarily sell medical supplies, devices, equipment and related services, where some equipment requires installation. Two performance obligations have been identified in customer contracts comprising delivery of medical equipment that includes installation, since both the equipment and the installation are deemed to be distinct performance obligations. The performance obligation for the sale of medical supplies, devices and equipment is satisfied when Asker's companies deliver the supplies and equipment in accordance with the delivery terms in the specific contract and control is thus transferred to the customer. Installation of medical equipment is a service that is recognised over time as it is performed. The same applies for service contracts.

	1 April–30 June		1 January–30 June		Full-year
Amounts in SEKm	2026	2025	2026	2025	2025
Sale of goods					
North	1,288	1,136	2,510	2,274	4,697
West	2,123	1,986	4,178	3,495	7,855
Central	848	666	1,679	1,360	2,670
Total goods	**4,260**	**3,657**	**8,367**	**7,129**	**15,223**
Sale of services					
North	140	128	273	253	512
West	204	34	402	534	688
Central	82	35	165	66	364
Total services	**427**	**329**	**840**	**853**	**1,564**
Total net sales	**4,686**	**3,987**	**9,207**	**7,982**	**16,787**

NOTE 3 Fair value of financial instruments

Asker's financial assets and financial liabilities measured at fair value through profit or loss refer to derivatives and liabilities related to contingent considerations arising in connection with acquisitions. For derivatives, the fair value is determined based on observable market data, meaning level 2 of the fair value hierarchy stipulated in IFRS 13. The closing balance for positive derivatives amounted to SEK 28m (7), and the closing balance for negative derivatives amounted to SEK 5m (34). Liabilities for contingent considerations are recognised based on the acquired company's earnings, meaning a multiple valuation based on future EBITDA or EBITA performance measures, discounted using the Group's discount rate, with future EBITDA/EBITA measures obtained from company management's best estimates based on adopted business plans, implying valuation in level 3 according to the fair value hierarchy. There were no transfers between levels during the period. Other assets and liabilities are recognised at amortised cost. The fair value of liabilities to credit institutions is estimated to be consistent with the carrying amount since the loans carry variable interest rates. The fair value of short-term borrowing corresponds to its carrying amount since the discount effect is not material. See below for a table of the changes in contingent considerations in level 3, from both business combinations and asset acquisitions.

Contingent consideration	30 June		31 December
Amounts in SEKm	2026	2025	2025
Opening balance	870	688	688
Acquisitions	177	79	215
Payments	–463	–156	–166
Remeasurement*	–14	56	96
Discount effect*	38	24	61
Reclassifications	–	–	8
Exchange rate differences	36	–16	–32
Closing balance	**645**	**674**	**870**

*The earnings effect of the remeasurement of contingent considerations amounts to SEK 14m (–56) and is recognised in other operating expenses. The impact of the discount effect is SEK –38m (–24) and is recognised in net financial items.

NOTE 4 Business combinations

As part of Asker's value creation, whereby organic growth is complemented with acquisitions of small and medium-sized companies to add new products, customer groups and/or channels and thus build a full-service offering and create a platform for a more efficient value chain for the healthcare sector, the following business combinations have been completed in 2026.

- On 2 February, the Group acquired 100% of the shares in Van Heek Medical (signed in the fourth quarter of 2025), a leading manufacturer and distributor of medical supplies in the Benelux region. The company had 64 employees and a sales of approximately SEK 350m in the most recent financial year. Identified excess values consist of customer relationships, trademarks and goodwill.
- On 3 February, the Group acquired 100% of the shares in German Healthcare (GHC) and Medicalprodukte Vertrieb Flensburg (MPF), two interlinked medical supplies companies within the home care segment in Germany. The companies had 140 employees and sales of approximately SEK 300m in the most recent financial year. Identified excess values consist of customer relationships, trademarks and goodwill.
- On 1 April, the Group acquired 100% of the shares in RMS Medical Devices, a fast-growing medical device distributor based in Belgium. The company had 25 employees and sales of approximately SEK 170m in the most recent financial year. Identified excess values consist of customer relationships, trademarks and goodwill.
- In June, it was decided that the Group would discontinue the acquisition of Kirstine Hardam in Denmark, which had been announced in June 2025, in full agreement with the company's owner.

Preliminary purchase price allocations for acquired identifiable net assets are provided below. Since individual disclosures about acquisitions are not material, disclosures are provided in aggregated form.

Acquired assets measured at fair value

Amounts in SEKm	Total for the period
Intangible assets	346
Tangible assets	9
Right-of-use assets	55
Inventories	136
Other current assets	160
Cash and cash equivalents	32
Deferred tax assets/liabilities	–88
Interest-bearing liabilities	–60
Lease liabilities	–55
Other operating liabilities	–107
Total identifiable net assets	**428**
Goodwill	266
Non-controlling interests	–
Consideration	**693**
Paid consideration	328
Outstanding consideration 2026	187
Contingent consideration	177
Total estimated consideration	**693**

Effect of acquisitions on cash flow

Amounts in SEKm	Total for the period
Paid consideration	–328
Cash and cash equivalents in acquired companies	32
Paid contingent consideration impacting investing activities*	–226
Total cash flows in investing activities	**–522**
Paid contingent consideration impacting operating activities*	–238
Total cash flow from operating activities	**–238**

* According to IFRS accounting policies, payments of contingent considerations must be allocated in the statement of cash flows between financing activities and operating activities based on how they have impacted initial purchase price allocations and earnings, respectively, in subsequent periods.

Other current assets mainly relate to accounts receivable. There is no material difference between acquired receivables and the gross amount, and there are no receivables that are not expected to be settled. Control was obtained through initial cash payments, forthcoming settlements of purchase considerations related to completed acquisitions, and contingent consideration agreements. Asker prepares preliminary purchase price allocations for the period during which there is uncertainty regarding the outcome of specific components of the acquisition agreements, for example, during the period that the company engages external valuation specialists and the external valuation has not yet been completed, or in cases when the final acquisition balance has not been received. However, the valuation period never extends for more than one year from the acquisition date. The purchase price allocations for acquisitions completed as of the third quarter of 2025 up to and including the second quarter of 2026 are preliminary since the Group has not received final, definitive information from the acquired companies. No material changes were made to the Group's purchase price allocations during the quarter with respect to acquisitions in the prior year.

Fair value adjustments to intangible assets generally comprise customer relationships, customer contracts and trademarks. Goodwill is justified based on high profitability and the personnel included in the acquired companies. For acquisitions, Asker usually applies an acquisition structure with basic consideration and possible contingent consideration. The contingent consideration is based on the earnings of the acquiree, implying a multiple valuation based on future EBITDA or EBITA performance measures, discounted using the Group's discount rate. Future EBITDA/EBITA performance measures are obtained from management's best estimate based on adopted business plans. Contingent consideration is initially measured at the present value of probable future outcomes, which for the acquisitions during the period has been estimated at SEK 177m (72). In total, contingent considerations for acquisitions completed during the period may amount to between SEK 0m and SEK 533m. No changes were made to the method for calculating consideration. Transaction costs for the acquisitions made during the period amounted to SEK 5m (22) and are included in administrative expenses in profit or loss.

The impact on the Group's net sales from the acquired companies since the acquisition date amounted to SEK 273m and the impact on the Group's EBITA since the acquisition date amounted to SEK 47m. If all acquired companies had been consolidated from 1 January 2026, net sales for the period would have amounted to SEK 9,303m and EBITA to SEK 911m.

NOTE 4 Business combinations, cont.

Completed acquisitions after the end of the reporting period

- On 3 July, the Group acquired 100% of the shares in Murray Surgical Limited, a leading distributor of specialist surgical and medical products to the healthcare sector in Ireland. The company had nine employees and sales of approximately SEK 73m in the most recent financial year. The purchase price allocation is ongoing and excess values are expected to consist of customer relationships and goodwill.

Acquisitions in the last two years

Year	Month of closure	Acquisitions	Business area	Country	Acquired shareholding	Net sales*, SEKm	No. of full-time equivalents
2026	April	RMS	West	Netherlands	100%	170	19
2026	February	GHC/MPF	Central	Germany	100%	300	117
2026	February	Van Heek Medical	West	Netherlands	100%	350	59
2025	December	Cardio Dépôt	Central	France	100%	25	5
2025	November	InnoMedicus	Central	Switzerland	100%	50	10
2025	October	Novus Med	West	UK	100%	80	12
2025	October	Finmed	Central	France	79%	380	62
2025	October	Dartin	Central	Czech Republic	100%	46	23
2025	September	Oudshoorn	West	Netherlands	100%	37	8
2025	August	HNC	West	UK	100%	60	19
2025	July	Scan Modul	West	Netherlands	100%	400	94
2025	July	ITAK	North	Estonia	100%	90	67
2025	May	MS Labors	Central	Austria	100%	23	5
2025	February	HSL Group	West	Ireland	97%	800	150
2025	February	Mayumana	West	Netherlands	100%	60	11
2024	November	Hauser	Central	Austria	100%	23	5
2024	November	Opitek	West	Denmark	100%	10	3
2024	October	Kvinto	North	Norway	100%	60	3
2024	September	Hugo	Central	UK	100%	81	84
2024	August	Aspironix	Central	Czech Republic	100%	200	70
2024	August	meetB	Central	Germany	100%	340	60
2024	August	Funktionsverket	North	Sweden	100%	30	2
2024	July	Wolturnus	West	Denmark	100%	150	71

* Estimated net sales at date of acquisition, annual basis

NOTE 5 Alternative performance measures

Certain information in Asker's interim report that is used by management and analysts to assess and evaluate the Group's financial position and earnings is not defined in accordance with IFRS Accounting Standards. The Group believes that the information aids the understanding of Asker's financial position and earnings. This information should be regarded as supplementary information and does not replace the consolidated financial statements prepared in accordance with IFRS.

Adjusted EBITA and adjusted EBITA margin, %	**1 April–30 June**		**1 January–30 June**		**Rolling 12 months**	**Full-year**
Amounts in SEKm	**2026**	**2025**	**2026**	**2025**	**2025/2026**	**2025**
Operating profit (EBIT)	349	249	659	487	1,181	1,009
Amortisation of intangible assets from acquisitions	96	56	186	111	363	288
Amortisation of intangible assets from operating activities	30	18	59	37	115	93
EBITA	**475**	**323**	**903**	**634**	**1,659**	**1,390**
Items affecting comparability						
Acquisition and integration expenses	9	15	20	37	73	90
Revaluation of contingent considerations	–17	39	–14	56	27	96
Other non-recurring items	3	1	4	15	7	18
Total items affecting comparability	**–4**	**55**	**9**	**108**	**106**	**204**
Adjusted EBITA	**471**	**378**	**912**	**742**	**1,765**	**1,594**
Net sales	4,686	3,987	9,207	7,982	18,012	16,787
Adjusted EBITA margin, % *(Adjusted EBITA/Net sales)*	**10.0%**	**9.5%**	**9.9%**	**9.3%**	**9.8%**	**9.5%**

EBITA growth	**Rolling 12 months**	**Full-year**
Amounts in SEKm	**2025/2026**	**2025**
Adjusted EBITA	1,765	1,594
Growth, current period compared with previous	21.3%	17.1%

EBITA margin	**1 April–30 June**		**1 January–30 June**		**Rolling 12 months**	**Full-year**
Amounts in SEKm	**2026**	**2025**	**2026**	**2025**	**2025/2026**	**2025**
EBITA	475	323	903	634	1,659	1,390
Net sales	4,686	3,987	9,207	7,982	18,012	16,787
EBITA margin	**10.1%**	**8.1%**	**9.8%**	**7.9%**	**9.2%**	**8.3%**

Adj. cash flow from operating activities	**1 April–30 June**		**1 January–30 June**		**Full-year**
Amounts in SEKm	**2026**	**2025**	**2026**	**2025**	**2025**
Cash flow from operating activities	92	211	511	320	1,328
Payment of contingent considerations that impacted operating activities	238	–	238	–	57
Adj. cash flow from operating activities	**330**	**211**	**749**	**320**	**1,385**

NOTE 5 Alternative performance measures, cont.

EBITDA adjusted for leases and items affecting comparability Amounts in SEKm	1 April–30 June 2026	2025	1 January–30 June 2026	2025	Rolling 12 months 2025/2026	Full-year 2025
Operating profit (EBIT)	349	249	659	487	1,181	1,009
Depreciation of tangible assets	130	101	251	198	488	435
Amortisation of intangible assets from acquisitions	96	56	186	111	363	288
Amortisation of intangible assets from operating activities	30	18	59	37	115	93
Operating profit (EBITDA)	**605**	**424**	**1,154**	**832**	**2,147**	**1,825**
Items affecting comparability	–4	55	9	108	106	204
Expenses attributable to leases	–97	–71	–191	–142	–354	–305
EBITDA adjusted for leases and items affecting comparability	**503**	**408**	**972**	**798**	**1,900**	**1,724**

Net debt Amounts in SEKm	30 June 2026	2025	31 December 2025
Non-current interest-bearing liabilities	4,256	3,361	4,223
Non-current interest-bearing liabilities to credit institutions	**4,256**	**3,361**	**4,223**
Current interest-bearing liabilities	1,033	850	557
Current interest-bearing liabilities to credit institutions	**1,033**	**850**	**557**
Cash and cash equivalents	777	1,325	884
Net debt	**4,511**	**2,886**	**3,896**

Debt/equity ratio Amounts in SEKm	30 June 2026	2025	31 December 2025
Net debt	4,511	2,886	3,896
Total equity	7,018	6,424	6,588
Debt/equity ratio	**0.6**	**0.4**	**0.6**

Net debt/EBITDA adjusted for leases and items affecting comparability Amounts in SEKm	30 June 2026	2025	31 December 2025
Net debt	4,511	2,886	3,896
EBITDA adjusted for leases and items affecting comparability, rolling 12 months	1,900	1,565	1,724
Net debt/EBITDA adjusted for leases and items affecting comparability	**2.37**	**1.84**	**2.26**

Capital employed Amounts in SEKm	30 June 2026	2025	31 December 2025
Total equity	7,018	6,424	6,588
Total interest-bearing liabilities	5,404	4,211	4,781
Contingent considerations	645	674	870
Compound call and put option	133	115	127
Total lease liabilities	1,073	897	1,033
Total capital employed	**14,273**	**12,321**	**13,399**

NOTE 5 Alternative performance measures, cont.

Return on capital employed	30 June		31 December
Amounts in SEKm	**2026**	**2025**	**2025**
Operating profit (EBIT), rolling 12 months	1,181	986	1,009
Average capital employed	13,632	10,946	12,456
Return on capital employed, %	**8.7%**	**9.0%**	**8.1%**
Goodwill from owner change 2019	–2,493	–2,493	–2,493
Adjusted average capital employed	11,139	8,453	9,963
Return on adjusted capital employed, %	**10.6%**	**11.7%**	**10.1%**

Net working capital	30 June		31 December
Amounts in SEKm	**2026**	**2025**	**2025**
Inventories	2,364	1,938	2,041
Accounts receivable	2,096	1,810	2,052
Accounts payable	–1,672	–1,348	-1,610
Advance payments from customers	–21	–20	-25
Total net working capital	**2,767**	**2,380**	**2,459**

Return on net working capital (EBITA/NWC), %	30 June		31 December
Amounts in SEKm	**2026**	**2025**	**2025**
Adjusted EBITA, rolling 12 months	1,765	1,454	1,594
Average net working capital	2,567	2,225	2,378
Return on net working capital (EBITA/NWC), %	**68.7%**	**65.4%**	**67.0%**

Earnings per share

Asker has calculated earnings per share in accordance with IAS 33, whereby profit attributable to the Parent Company has been adjusted for the interest component of preference shares, with adjustment being made for the number of common shares received after the conversion of preference shares to common shares in conjunction with the IPO, and the number of shares has been calculated based on the basis of the average number of shares outstanding. As an alternative performance measure, Asker has calculated earnings per share based on recognised profit or loss for the period, and as if the effects of the new share issue, the set-off issue and the conversion of preference shares to common shares had taken place before the start of the initial comparative period.

	1 April–30 June		1 January–30 June		Rolling 12 months	Full-year
	2026	**2025**	**2026**	**2025**	**2025/2026**	**2025**
Profit or loss attributable to Parent Company's shareholders (SEKm)	219	129	412	220	683	492
Adjustment for interest component of preference shares (SEKm)	–	–	–	–31	–	–31
Adjusted profit or loss attributable to Parent Company's shareholders (SEKm)	219	129	412	189	683	461
Average number of common shares outstanding	383,036,497	383,036,497	383,036,497	353,294,482	383,036,497	368,248,106
Earnings per share (SEK)	**0.57**	**0.34**	**1.07**	**0.54**	**1.78**	**1.25**
Profit or loss attributable to Parent Company's shareholders (SEKm)	219	129	412	220	683	492
Total number of common shares outstanding	383,036,497	383,036,497	383,036,497	383,036,497	383,036,497	383,036,497
Adjusted earnings per share (SEK)	**0.57**	**0.34**	**1.07**	**0.57**	**1.78**	**1.28**

Financial key performance indicators

	2026		2025				2024		
Amounts in SEKm unless otherwise stated	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2
Net sales	4,686	4,521	4,676	4,129	3,987	3,995	4,303	3,597	3,669
EBITA	475	428	407	348	323	311	359	272	326
EBITA margin, %	10.1%	9.5%	8.7%	8.4%	8.1%	7.8%	8.3%	7.6%	8.9%
Adjusted EBITA	471	442	470	383	378	364	406	306	338
Adjusted EBITA margin, %	10.0%	9.8%	10.0%	9.3%	9.5%	9.1%	9.4%	8.5%	9.2%
EBITDA adjusted for leases and items affecting comparability	503	469	511	417	408	389	433	335	364
Capital employed	14,273	14,074	13,399	12,780	12,321	11,324	10,247	9,894	9,169
Average capital employed	13,632	13,143	12,456	11,668	10,946	10,158	9,615	9,211	8,901
EBIT	349	310	281	242	249	237	287	212	271
Return on capital employed, %	8.7%	8.2%	8.1%	8.7%	9.0%	9.9%	10.0%	8.2%	7.5%
Return on adjusted capital employed, %	10.6%	10.2%	10.1%	11.1%	11.7%	13.2%	13.6%	11.2%	10.5%
Total assets	17,832	17,753	16,774	15,937	15,208	14,234	13,118	12,631	11,825
Equity	7,018	6,871	6,588	6,509	6,424	6,239	3,502	3,356	3,297
Profit for the period	225	197	136	146	133	95	108	82	117
Net debt	4,511	3,871	3,896	3,648	2,886	2,585	3,091	3,113	2,702
Net debt/EBITDA adjusted for leases and items affecting comparability	2.4	2.1	2.3	2.2	1.8	1.7	2.1	2.2	2.1
Debt/equity ratio	0.6	0.6	0.6	0.6	0.4	0.4	0.9	0.9	0.8
Net working capital	2,767	2,619	2,459	2,425	2,380	2,250	2,157	2,112	1,982
Average net working capital	2,567	2,470	2,378	2,303	2,225	2,125	2,020	1,917	1,846
Return on net working capital (EBITA/NWC), %	68.7%	67.7%	67.0%	66.5%	65.4%	66.5%	67.4%	66.3%	65.6%
Adjusted cash flow from operating activities	330	419	568	439	211	109	459	223	308

	1 January–30 June		Rolling 12 months	Full-year
Amounts in SEKm unless otherwise stated	2026	2025	2025/2026	2025
Net sales	9,207	7,982	18,012	16,787
EBITA	903	634	1,659	1,390
EBITA margin, %	9.8%	7.9%	9.2%	8.3%
Adjusted EBITA	912	742	1,765	1,594
Adjusted EBITA margin, %	9.9%	9.3%	9.8%	9.5%
EBITDA adjusted for leases and items affecting comparability	972	798	1,900	1,724
Average capital employed	13,632	10,946	13,631	12,456
Return on capital employed, %	8.7%	9.0%	8.7%	8.1%
Net debt	4,511	2,886	4,511	3,896
Net debt/EBITDA adjusted for leases and items affecting comparability	2.4	1.8	2.4	2.3
Debt/equity ratio	0.6	0.4	0.6	0.6
Average net working capital	2,567	2,225	2,567	2,378
Return on net working capital (EBITA/NWC), %	68.7%	65.4%	68.7%	67.0%
Average number of full-time equivalents	4,053	3,560	3,937	3,695
Number of employees at the end of the period	4,885	4,248	4,885	4,559
Adjusted cash flow from operating activities	749	320	1,814	1,385
Earnings per share before and after dilution (SEK)	1.07	0.54	1.78	1.25
Earnings per share before and after dilution (SEK), adjusted*	1.07	0.57	1.78	1.28

* Refer to Note 5 for the calculation of alternative performance measures.

Definitions

KEY PERFORMANCE INDICATORS	DEFINITIONS	PURPOSE
EBITA	Operating profit before amortisation and impairment of intangible assets.	EBITA provides an overall view of profit generated by operations and is a metric that the Group considers to be relevant for investors who want to understand earnings generation before amortisation of intangible assets.
EBITA margin, %	EBITA as a percentage of net sales.	The KPI is used to measure the company's profitability before amortisation and impairment of intangible assets.
Items affecting comparability	Acquisition and integration expenses, revaluation of contingent considerations, as well as other non-recurring items deemed to affect comparability.	Items affecting comparability make adjustments for items that are not deemed to reflect the underlying operations.
Adjusted EBITA	EBITA excluding items affecting comparability.	The KPI increases comparability of EBITA over time since it makes adjustments for the impact of items affecting comparability that are considered to be of a non-recurring nature and therefore do not reflect the underlying operations.
Adjusted EBITA margin, %	Adjusted EBITA as a percentage of net sales.	The KPI is used to measure the company's profitability excluding the impact of acquisition and integration expenses and other items affecting comparability.
Organic growth	Year-on-year change in net sales or profit/loss, excluding exchange rate effects, from entities that have been part of the Group for at least 12 months. Growth that arises when Group companies take over specific assets (asset acquisitions) from other operators is normally considered organic growth. This could take the form of the Group taking over distribution contracts and paying a compensation fee to a previous operator.	Organic growth is used to illustrate growth from the underlying business operations adjusted for the effects of currency and acquisitions.
EBITA growth	Percentage change in EBITA between two periods.	The KPI is used to measure the company's earnings growth.
EBITDA adjusted for leases and items affecting comparability	Operating profit before depreciation, amortisation and impairment of tangible and intangible assets less actual rent costs attributable to leases and items affecting comparability.	The metric shows the company's earnings generation before investments in non-current assets as if all leases had been recognised as operating leases and adjusted for acquisition and integration expenses and other items affecting comparability.
Adjusted cash flow from operating activities	Cash flow from operating activities, adjusted for payments of contingent considerations that, under IFRS Accounting Standards, must be presented under operating activities in the statement of cash flows.	This metric shows the company's underlying cash flow from operating activities.
Capital employed	Equity and interest-bearing liabilities including contingent considerations and liabilities related to compound call and put options.	Capital employed is a metric that the Group considers to be relevant for investors who want to understand the company's net assets that are to generate profit.
Adjusted capital employed	Equity and interest-bearing liabilities including contingent considerations and liabilities related to combined call and put options less the goodwill arising from the change of ownership in 2019.	The metric adjusts capital employed by the goodwill that arose from the change of ownership in 2019 to better reflect the capital of the underlying operations.
Average capital employed/ adjusted capital employed	Average capital employed/adjusted capital employed for the four most recent quarters.	The measure provides an understanding of capital employed/adjusted capital employed over time and is used to calculate the return on capital employed.
Return on capital employed/ adjusted capital employed, %	Operating profit (EBIT) rolling 12 months as a percentage of average capital employed/adjusted capital employed.	The metric is an indication of how efficient the Group is at utilising its capital resources.
Net debt	Non-current and current interest-bearing liabilities to credit institutions less cash and cash equivalents.	This KPI is used as a supplement to assess the feasibility of paying dividends and making strategic investments, and for assessing the Group's ability to meet its financial commitments.
Net debt/EBITDA adjusted for leases and items affecting comparability	Net debt as a percentage of EBITDA less actual rent costs attributable to leases and items affecting comparability, rolling 12 months.	This KPI is a debt ratio that shows how many years it would take to pay off the company's debt, provided that its net debt and EBITDA are constant and without taking into account cash flows for interest, tax and investments.
Debt/equity ratio	Net debt as a percentage of equity.	The metric shows the proportion of net debt as a percentage of equity.
Net working capital	Total of inventories and accounts receivable less accounts payable and advance payments from customers.	This metric shows the capital that the company has available to finance the operating activities.

KEY PERFORMANCE INDICATORS	DEFINITIONS	PURPOSE
Average net working capital	Total of inventories and accounts receivable less accounts payable and advance payments from customers, average for the four most recent quarters.	The measure provides an understanding of working capital over time and is used to calculate the return on net working capital.
Return on net working capital (EBITA/NWC), %	Adjusted EBITA rolling 12 months as a percentage of average net working capital.	The KPI is used to analyse profitability and is a metric that puts a premium on high EBITA and low net working capital requirements.
Cash flow from operating activities	Total of cash flow for the period from operating activities.	Cash flow is used to provide an overview of the cash and cash equivalents that flow in and out of the operations.
Average number of full-time equivalents	Calculated as the average number of employees for the year, taking into account the percentage of full-time employment.	The metric can be used to compare specific key performance indicators in relation to average employees.
Number of employees at the end of the period	The number of employees in the Group at the end of the period.	This metric is used to know how many employees the Group has at the end of a given period.
Earnings per share	Profit for the period, adjusted for the amount related to the settlement of preference shares, attributable to the Parent Company's shareholders divided by the average number of common shares outstanding.	Earnings per share is used to determine the value of the company's average number of common shares outstanding.
Adjusted earnings per share	Recognised profit for the period attributable to the Parent Company's shareholders divided by the total number of common shares outstanding.	Adjusted earnings per share is used to determine the value of the company's total number of common shares outstanding.

About Asker Healthcare Group

Leading provider of medical products and solutions – Driving progress in the European healthcare sector.

Asker Healthcare Group is a European leading provider of medical products and solutions.

Over the past decade we have organically and via acquisitions built a pan-European group with deep knowledge in healthcare, attracting entrepreneurs that together with us want to drive progress and support the healthcare sector to improve patient outcomes, reduce the total cost of care and ensure a fair and sustainable value chain.

By combining entrepreneurial responsibility with a distinct steering model, we have created a solid platform for growth with continuous acquisitions in the large and fragmented European market.

Today, the Group consists of more than 50 companies in 19 countries and more than 5,000 employees, and brings significant scale and knowledge sharing, to the benefit of the Group and the healthcare sector.

We are "Health in progress".



Asker's strategy for value creation – its twin engine – is built on two distinct but interlinked components that combine organic growth with acquisitions.

Financial calendar

	Date
Interim Report – Q3 2026	4 November 2026
Year-end report	10 February 2027

Additional information

Investors and analysts
Thomas Moss, CFO and Head of IR
Tel: +46 70 219 79 05
E-mail: ir@asker.com

Media
Emma Rheborg, Head of Communication
Tel: +46 73 313 62 17
E-mail: emma.rheborg@asker.com

This information is such information that Asker Healthcare Group AB (publ) is obligated to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8:10 a.m. CEST on 21 July 2026.



asker.com/sustainability/sustainability-reporting/msci

Address: Asker Healthcare Group AB
Svärdvägen 3A, SE-182 33 Danderyd, Sweden
www.asker.com